Table 2.
Differences between HER2DX (2022) and HER2DX (2020) content
| HER2DX (2020) | HER2DX (2022) | |||
|---|---|---|---|---|
| Clinical feature | Tumour size, Nodal status, Number of tumour-infiltrating lymphocytes (TILS), PAM50 subtype | Tumour size, Nodal status | ||
| Genomic feature | Genes associated with better survival outcome (6 genes): | Genes related to luminal differentiation (BAG1) | Immunoglobulin (IGG) module (14 genes): | CD27, CD79A, HLA-C, IGJ, IGKC, IGL, IGLV3-25, IL2RG, CXCL8, LAX1, NTN3, PIM2, POU2AF1 and TNFRSF17 |
| Genes related to the normal cell phenotype (KRT5, KRT14, MLPH, MYC) | The tumour cell proliferation signature (4 genes): | EXO1, ASPM, NEK2 and KIF23 | ||
| Basal-like-related genes (PHGDH) | The luminal differentiation signature (5 genes): | BCL2, DNAJC12, AGR3, AFF3 and ESR1 | ||
| Genes associated with poor survival outcomes (7 genes): | Genes related to proliferation (CDC6, EXO1, RRM2) | The HER2 amplicon signature (4 genes): | ERBB2, GRB7, STARD3 and TCAP | |
| Genes related to HER2 amplicion (TMEM45B, FGFR4) | ||||
| Basal-like-related biology (CDH3) | ||||
| Genes related to cell invasion (MMP11) | ||||
| Application | Predicting survival outcomes | Predicting survival outcomes, the likelihood of pathological remission from treatment, and assessing ERBB2 expression | ||